Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
September 20 2016 - 4:01PM
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the
closing of its previously announced underwritten public offering of
common stock, including the exercise in full by the underwriters of
their option to purchase an additional 505,617 shares at the public
offering price of $44.50 per share. The exercise of the option to
purchase additional shares brought the total number of shares of
common stock sold by Agios to 3,876,403 shares and increased the
amount of gross proceeds raised in the offering, before
underwriting discounts and estimated expenses of the
offering, to approximately $173 million.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. acted as
joint book-running managers for the offering. Cowen and Company,
LLC served as lead manager.
The shares were offered by Agios pursuant to an automatically
effective shelf registration statement that was previously filed
with the Securities and Exchange Commission (“SEC”). A prospectus
supplement relating to, and describing the terms of, the offering
has been filed with the SEC and is available on the SEC’s web site
at www.sec.gov. Copies of the prospectus supplement and the
accompanying prospectus relating to this offering can be obtained
from J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717,
telephone: 866-803-9204; or Goldman, Sachs, & Co., Attn:
Prospectus Department, 200 West Street, New York, New York 10282,
telephone: 866-471-2526, facsimile: 212-902-9316, e-mail:
prospectus-ny@ny.email.gs.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Agios Pharmaceuticals, Inc. Agios is
focused on discovering and developing novel investigational
medicines to treat cancer and rare genetic metabolic disorders
through scientific leadership in the field of cellular metabolism.
In addition to an active research and discovery pipeline across
both therapeutic areas, Agios has multiple first-in-class
investigational medicines in clinical and/or preclinical
development. All Agios programs focus on genetically identified
patient populations, leveraging our knowledge of metabolism,
biology and genomics.
Cautionary Note Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, such as those, among others, relating to Agios’
intended use of proceeds from the public offering. The words
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,”
“plan,” “predict,” “project,” “would,” “could,” “potential,”
“possible,” “hope” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties
related to the impact of general economic, industry or political
conditions in the United States or internationally. You should not
place undue reliance on these forward-looking statements.
Additional risks and uncertainties relating to the offering, Agios
and its business can be found under the caption “Risk Factors”
included in Agios’ Quarterly Report on Form 10-Q for the quarter
ended June 30, 2016, Agios’ prospectus supplement filed with the
SEC on September 15, 2016, and other filings that Agios may make
with the SEC in the future. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Agios expressly disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACTS:
Kendra Adams, Senior Director, Investor & Public Relations
Kendra.Adams@agios.com
617-844-6407
Renee Leck, Senior Manager, Investor & Public Relations
Renee.Leck@agios.com
617-649-8299
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2024 to May 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From May 2023 to May 2024